Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other financing activities (2016 - 2025)

Altimmune (ALT) has disclosed Other financing activities for 6 consecutive years, with $322000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities changed N/A to $322000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $340351.0, a N/A change, with the full-year FY2016 number at $612218.0, changed N/A from a year prior.
  • Other financing activities was $322000.0 for Q3 2025 at Altimmune, up from $18351.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $322000.0 in Q3 2025 to a low of $322000.0 in Q3 2025.